Partners

Covance Inc.
Myriad RBM has a biomarker alliance and services agreement with Covance Inc. (NYSE:CVD) that will provide biotechnology and pharmaceutical companies with a powerful combination of biomarker technologies and services for use in drug development. Under terms of the agreement, Covance will use Myriad RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and Myriad RBM shall use Covance as its exclusive referral source for laboratory testing services.

About Covance Inc.
Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 10,000 employees worldwide. Information on Covance’s products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.